Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Identifying drivers of resistance in childhood brain tumours

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.05.18
Views: 228

Dr Pratiti Bandopadhayay - Dana-Farber Cancer Institute, Boston, USA

Dr Bandopadhayay speaks with ecancer at the Cancer Research UK Brain Tumour Conference 2018 in London about resistance mechanisms in paediatric brain tumours.

Taking cues from treatment resistance in melanoma, she describes how BRAF targeted therapies may be subverted by genetic rearrangement, and the prospects of immunotherapies in childhood patients.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence